Cramer's Morning Take: Eli Lily 5/1/25

SPEAKER_1 (0:01)

Introducing Instagram Teen Accounts. A new way to keep your teen safer as they grow, like making sure they always have their seatbelt on.

SPEAKER_2 (0:09)

All right, sweetie pie, buckle up. Good job.

SPEAKER_1 (0:12)

Or ring the bell on their bike.

Jim Cramer (0:13)

Okay, kid, give it a try.

SPEAKER_4 (0:16)

Nice.

SPEAKER_1 (0:17)

Or remember their elbow pads.

SPEAKER_4 (0:19)

Knees too, okay? There you go.

SPEAKER_1 (0:22)

New Instagram Teen Accounts. Automatic protections for who can contact your teen and the content they can see.

SPEAKER_4 (0:31)

Hey, Fidelity, what's it cost to invest with the Fidelity app?

SPEAKER_5 (0:36)

Start with as little as $1 with no account fees or trade commissions on US stocks and ETFs.

SPEAKER_4 (0:43)

That's music to my ears.

SPEAKER_5 (0:45)

I can only talk.

SPEAKER_1 (0:48)

Investing involves risk, including risk of loss.

SPEAKER_4 (0:49)

Zero account fees apply to retail brokerage accounts only.

SPEAKER_1 (0:51)

Zero dollar commission applies to online US equity trades and ETFs and retail Fidelity accounts.

SPEAKER_4 (0:54)

Sell order assessment fee not included.

SPEAKER_6 (0:55)

Some account types and securities excluded.

SPEAKER_4 (0:56)

Details at fidelity.com/commissions. Fidelity Brokerage Services LLC member NYSE SIPC.

Jim Cramer (1:04)

Jim Cramer here to share with you a sample of my take on the market from today's CNBC Investing Club morning meeting.

SPEAKER_6 (1:12)

Let's talk Lily, because I think the good results are being overshadowed by announcements by CVS. So it was a top and bottom line beat. You did have a revenue beat for the DLP one franchise, both ZetBound and Manjaro. Slightly beat expectations. It wasn't a big beat, but one percent. But they did have a miss in the last couple of quarters, so this was positive to see. Call just started at 10, so not on it, but the news that's really impacting the stock is CVS says today, formed a partnership with Nova Nordis. Starting July 1st, CVS Caremark will prioritize Wigovie on its list of covered drugs, making it the preferred GLP-1 for obesity. Some concern that this will slow script momentum for Eli Lily's products. It also could impact pricing too, right? So again, I'm sure it's being addressed on the call that's happening right now, but the big reason why Lily had the spike from the low 700s just the other week was good data on their pill, the obesity pill, or for Glipron.

Jim Cramer (2:13)

Which is not going away, it's just getting closer and closer.

SPEAKER_6 (2:16)

Sure, and it gives you a Govee-like efficacy with solid tolerability, good safety profile. It's once daily versus once weekly injection. People are going to prefer to take the pill. It's just easier to use.

Jim Cramer (2:28)

By the way, it doesn't have to be kept cold, so it's ideal to ship to China and India, where there are 200 million people, David, that are going to need it.

SPEAKER_6 (2:35)

So storage-wise, there's also benefits as well, really important.

Jim Cramer (2:38)

Let's just talk trading for a second. Okay, so, you're holding it because you thought it was going to be a blowout quarter, you didn't expect the CBS, so now you're dumping it. Now, when do you get back in if you're one of those people? Do you get back in betting that the pill comes out, they have positive data, there's to be something good for the FDA? You don't know when to get back in, so the answer is don't leave.

SPEAKER_6 (2:56)

Yeah, and that pill, Rick thinks it could be approved as soon as early next year. They've pre-built inventory for it, so the launch, they are ready, no supply shortage, just like what the drugs have been facing for quite some time, although not in shortage anymore.

Jim Cramer (3:13)

Join the CNBC Investing Club with Jim Cramer to catch my member-exclusive warning minis every day at 10:20 a.m. Visit cnbc.com/morningtake to become a member today. That's one word, morning take.

SPEAKER_2 (3:30)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC, NBCUniversal, or their parent company or affiliates, and may have been previously disseminated by Cramer on television, radio, internet, or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment, or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Cramer. To view the full CNBC Investing Club Disclaimer, please visit cnbc.com/investingclubdisclaimer.